AI’s surging energy demand is creating new winners

AI workloads are scaling and data centers are expanding rapidly — driving unprecedented demand for electricity, cooling, and grid infrastructure.

Massive capital is flowing to the companies that enable AI at scale — the power producers, infrastructure owners, and critical technology suppliers behind the scenes.

In this FREE report, we reveal five publicly traded companies positioned to benefit directly from the AI energy buildout.

Inside, you’ll discover:

• A data-center landlord gaining pricing power
• A stealth REIT pivoting to AI infrastructure
• A monopoly supplier embedded in advanced AI chips
• A nuclear power leader partnering with Big Tech
• An industrial firm modernizing the electric grid

As AI growth increasingly depends on energy and infrastructure, these companies sit at the center of the next opportunity.

👉 Click here to see the 5 stocks positioned for AI’s biggest energy demand shift in decades

(By clicking the links above, you agree to receive future emails from us and bonus subscriptions from our partners. You can opt out at any time. - Privacy Policy)

To Your Trading Success,
The Stock Alert Daily Team

FB Financial's Southern Expansion and Buybacks Drive Analyst Optimism

Author: Peter Frank. Published: 9/4/2026.

Investors who don’t live in the South might not know Nashville-based FB Financial (NYSE: FBK). But perhaps they should.

The banking company is a year into absorbing a major Southern acquisition, while earnings surge, loans grow, and aggressive buybacks boost shareholder returns.

Moderna Doubled in One Day. This Medical Stock Could Be Next (Ad)

Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.

It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.

Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States.

Click here to learn about this new era of medical technology

All seven analysts covering FBK have issued a Buy or Strong Buy rating on the stock. Since July, two analysts have also raised their price targets.

Overall, the consensus 12-month price target is $64.67, implying about 15% upside. The highest 12-month target is $67, while the lowest is $63. That tight range suggests analysts are broadly aligned on FB Financial’s current valuation.

Southern States Deal Expands FB Financial’s Southeast Footprint

Much of the past year’s growth came as the company, parent of FirstBank, expanded its footprint across Tennessee, Alabama, Kentucky, and Georgia.

In July 2025, the company closed its acquisition of Southern States Bancshares, parent of Southern States Bank in Anniston, Alabama, in a deal valued at roughly $368.4 million at closing.

The merger immediately added $2.9 billion in assets, $2.3 billion in loans, and $2.5 billion in deposits, significantly expanding FB Financial’s scale across the Southeast.

In its Q2 2026 earnings report, FB Financial reported net income of $58.6 million, or GAAP diluted earnings per share (EPS) of $1.13, compared with $2.9 million, or six cents per share, a year earlier. Non-GAAP EPS came in at $1.14, up from 88 cents a year earlier and essentially matching the consensus estimate of $1.14. The sharp increase in earnings was amplified by a large securities loss in the prior-year quarter, but the adjusted results still show meaningful underlying earnings growth.

Revenue of $174.75 million was more than double the year-ago figure, though it came in slightly below Wall Street’s forecast.

Organic Loan and Deposit Growth Strengthens the Story

Beyond the acquisition-driven increase in scale, FB Financial is also seeing solid underlying growth in loans, deposits, and net interest income.

Total assets stood at $16.8 billion as of the second quarter, up from $13.4 billion a year ago. However, the more important signal is what happened after the deal: Loans grew at an 11.6% annualized pace, while noninterest-bearing deposits increased at a 16.7% annualized rate.

For a regional bank, that combination matters. Loan growth provides additional earning assets, while growth in noninterest-bearing deposits can help keep funding costs under control. Net interest income climbed to $149 million from $146 million in the prior quarter and $111.4 million a year earlier.

Pre-tax, pre-provision net revenue rose roughly 8% to $83.3 million over the past three months, pushing that profitability measure above 2% of average assets. Management nevertheless remains more measured about the full year, guiding for mid- to high-single-digit loan growth and a core net interest margin of 3.7% to 3.8%, excluding purchase-accounting accretion.

Dividend Growth and Buybacks Support Per-Share Returns

Returning capital to shareholders is also part of the picture.

FB Financial’s board raised the quarterly dividend 10.5% to 21 cents per share in January 2026.

At current prices, that works out to a dividend yield near 1.5%, modest by bank-stock standards. However, the approximately 22.5% payout ratio leaves considerable earnings available for growth and additional capital returns.

Buybacks have become the larger lever.

The board authorized a new $175 million share-repurchase program in April 2026, which runs through June 2027.

The company has been using this approach aggressively, buying back 3% of its outstanding shares in the second quarter alone.

A lower share count can magnify per-share earnings growth if operating performance continues to improve.

Integration and Credit Quality Remain the Key Risks

Although the company’s books show limited risks, investors should keep an eye on a couple of key issues.

The biggest risk is probably execution. FB Financial completed a $478 million merger with Franklin Financial Network in 2020, expanding its Nashville-area footprint. With the Southern States purchase, the company has now taken on a second sizable acquisition. Integrating Southern States while continuing to grow loans in the double digits leaves less room for error.

FB Financial also hit a bump in its loan portfolio in the second quarter. The company’s nonperforming loans as a percentage of total loans increased to 1.17% by the end of the quarter, compared with just 0.96% in the prior quarter.

That increase, however, was not systemic. The rise in nonperforming loans during the second quarter was concentrated in three borrower-specific relationships rather than being evidence of broader portfolio weakness. Overall net charge-offs remained low at six basis points annualized, and the allowance ratio held at 1.51%.

Like any regional bank, FB Financial also faces competition. The company competes with Southeast peers such as Pinnacle Financial Partners (NYSE: PNFP), Ameris Bancorp (NASDAQ: ABCB), First Horizon (NYSE: FHN), and Regions Financial (NYSE: RF), all of which are competing for the same growing Southeast deposit and lending base.

What Investors Should Watch Ahead of Q3 Earnings

With less than $20 billion in assets, FB Financial is not a major banking institution. But its fundamentals stand on their own.

Adjusted earnings are growing, loans and low-cost deposits continue to expand, and credit costs remain relatively low.

At the same time, the company is returning capital through dividends and share repurchases.

The question now is whether FB Financial can maintain that momentum as the acquisition moves further into the integration phase.

There are risks, but they appear manageable. The integration is still fresh, and a handful of borrower-specific credit flags need to continue resolving cleanly.

Investors who understand regional banking could find some value, while more cautious investors might want to wait for next month’s third-quarter earnings release to see whether loan growth, margins, and credit quality remain on track.

Accelerant’s Take-Private Deal Raises a Bigger Question for Insurance Stocks

Author: Nathan Reiff. Published: 9/4/2026.

Accelerant Holdings (NYSE: ARX) jumped into view for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, rather than an unglamorous firm connecting specialty insurance risk across a network of capital providers. Investors, therefore, may underestimate Accelerant's performance potential.

Accelerant's major breakthrough on Aug. 13 came as a result of two overlapping catalysts. First, the company reported unusually strong Q2 2026 earnings results. At the same time, the firm announced that it would be taken private by Thoma Bravo. Investors may be too late to maximize their gains on ARX stock, but the massive jump reveals important lessons about the specialty insurance industry that may pay off in other cases.

The First Major Driver: Extraordinary Earnings

Moderna Doubled in One Day. This Medical Stock Could Be Next (Ad)

Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.

It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.

Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States.

Click here to learn about this new era of medical technology

Accelerant's earnings for the latest quarter were stellar, topping Wall Street expectations across multiple critical metrics. With nearly $357 million in quarterly revenue, Accelerant improved this figure by about 63% year over year (YOY). Earnings per share (EPS) of 32 cents were more than double the 14 cents reported a year earlier. Both top- and bottom-line figures were significantly higher than Wall Street's already optimistic predictions.

The magnitude of Accelerant's EPS beat, in particular, is a sign that profitability is expanding at a breakneck pace. In Q2 2025, net income attributable to common shareholders was $8.8 million. By the same quarter this year, it had climbed to nearly $79 million. Adjusted EBITDA also made major gains, showing very healthy operating performance across multiple segments.

How Accelerant's Business Stands Out

Accelerant does not function like most insurance companies, which underwrite risk using their own balance sheets. Instead, it operates a specialty insurance exchange that connects capital providers, reinsurers, institutional investors and agents. Accelerant generates fee-based income from policies written through its exchange, allowing it to avoid taking on the insurance risk itself. This is crucial for the firm's margin growth: It can expand without taking on greater balance sheet exposure.

The company is expanding its capacity through key partnerships with third-party-capitalized insurer WoodStar Reciprocal, among others. This should help Accelerant scale its fee revenue, which may further distinguish the company from its industry peers. As Accelerant attracts more capital to its platform, it can facilitate more risk and generate larger volumes of fee income without increasing its own balance sheet risk.

The Second Major Driver: A Private Equity Deal

Thoma Bravo plans to take Accelerant private in an all-cash transaction with an enterprise value of more than $4 billion, valuing the shares at $20.25 each. This represented a significant premium over Accelerant's pre-announcement price, but after the brief spike, the shares have stabilized just below that level.

While the Thoma Bravo deal may not present much of an investment opportunity now that it has been announced and investors have reacted accordingly, it does suggest that specialty insurance marketplace models may be undervalued elsewhere in the market. Thoma Bravo specializes in insurance technology platforms and is unlikely to have paid a premium approaching 50% without determining that Accelerant was trading well below its true value.

Investors might view this as an opportunity to identify other insurance companies operating outside the traditional model, perhaps utilizing Accelerant's low-capital, fee-heavy exchange model or something similar.

This Opportunity May Have Passed, But Others Could Await

ARX shares are currently trading slightly below the $20.25 take-private price as investors factor in deal-completion risk, regulatory timelines and other concerns. While there may be some potential arbitrage opportunities, it seems unlikely that Accelerant will see another one-day gain like the one it experienced in August.

Investors may want to avoid spending too much time on ARX and instead assess what about the company warranted such a premium from Thoma Bravo before seeking out those same qualities elsewhere. Two of Accelerant's competitors that may see a boost in investor attention following the announcement are Ryan Specialty Group Inc. (NYSE: RYAN) and Kinsale Capital Group Inc. (NYSE: KNSL). Although their share price performance has not been as strong over the last month, both firms now trade in a market that has provided evidence of what a successful specialty insurance platform may be worth to investors.